Integer (NYSE:ITGR) Given New $145.00 Price Target at KeyCorp

Integer (NYSE:ITGR) had its price objective reduced by investment analysts at KeyCorp from $154.00 to $145.00 in a report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. KeyCorp’s target price indicates a potential upside of 22.75% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Raymond James assumed coverage on shares of Integer in a report on Friday, March 28th. They set an “outperform” rating and a $145.00 price target on the stock. Truist Financial reduced their price objective on shares of Integer from $163.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, April 11th. Finally, Benchmark lifted their target price on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.00.

Integer Stock Performance

ITGR opened at $118.12 on Monday. Integer has a 12-month low of $104.93 and a 12-month high of $146.36. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 1.72 and a beta of 1.09. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The company’s 50 day moving average is $120.73 and its 200 day moving average is $130.42.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. On average, equities research analysts predict that Integer will post 6.01 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ITGR. Capital Research Global Investors lifted its position in shares of Integer by 16.0% in the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider’s stock worth $186,960,000 after buying an additional 194,895 shares in the last quarter. Loomis Sayles & Co. L P raised its holdings in shares of Integer by 3.8% during the 4th quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider’s stock worth $74,041,000 after acquiring an additional 20,688 shares in the last quarter. Congress Asset Management Co. boosted its position in shares of Integer by 4.9% during the 1st quarter. Congress Asset Management Co. now owns 522,656 shares of the medical equipment provider’s stock valued at $61,679,000 after acquiring an additional 24,306 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in shares of Integer by 5.5% in the fourth quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider’s stock valued at $59,828,000 after purchasing an additional 23,706 shares in the last quarter. Finally, Northern Trust Corp increased its position in Integer by 14.2% in the fourth quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider’s stock worth $55,974,000 after purchasing an additional 52,556 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.